Age: 26.0
Sex: M
Vaccine: COVID19
Symptoms: Anosmia, COVID-19, Drug ineffective, Dyspnoea, Nasal congestion
Clinical narrative: Contracted COVID-19 symptomatically; contracted the COVID-19 virus and its symptomatic with the virus now; Contracted COVID-19 symptomatically; contracted the COVID-19 virus and its symptomatic with the virus now; Fever; Congestion; Shortness of breath; Lost sense of smell; This is a spontaneous report from a contactable consumer.  A 27-year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 2 via an unspecified route of administration, administered in Arm Left on 19Jan2021 (Lot Number: EL3247, Expiration date: 31May2021) at the age of 26 years as single dose, and dose 1 via an unspecified route of administration, administered in Arm Left on 29Dec2020 (Lot Number: EH9899, Expiration date: 31Mar2021) at the age of 26 years as single dose,  for covid-19 immunisation. The patient medical history was not reported. Concomitant medications included multivitamin like is generic multivitamin of men, a chewable Vitamin D3, and L-Lysine. On unspecified date the patient contracted covid-19 symptomatically; contracted the covid-19 virus and its symptomatic with the virus now, experienced fever, congestion, shortness of breath, lost sense of smell. Therapeutic measures taken as a result of the event contracted covid-19 symptomatically, included Sudafed 120 mg once a day and Ibuprofen 400 mg twice a day first 3 days. The outcome of the events was unknown. Subsequently Product Quality Complaint Group provided the following conclusions: Conclusion: The complaint for lack of effect of the PFIZER-BIONTECH COVID-19 VACCINE lot EH9899 was investigated. The investigation included a review of manufacturing and packaging batch records, deviation investigations, and an analysis of complaint history for the reported lot. The final scope included the reported finished goods lot EH9899, fill lot EH9783, and the formulated drug product lot EH9782. A complaint sample was not returned, and photographs were not received. No related quality issues were identified during the investigation. There is no impact to product quality. No root cause or corrective/preventative actions were identified as the complaint was not confirmed. All release testing performed prior to the release of the reported batch was within specifications. Conclusion: The complaint for lack of effect of the PFIZER-BIONTECH COVID-19 VACCINE lot EL3247 was investigated. The investigation included a review of manufacturing and packaging batch records, deviation investigations, and an analysis of complaint history for the reported lot. The final scope included the reported finished goods lot EL3247, fill lot EL3230, and the formulated drug product lot EL3223. A complaint sample was not returned, and photographs were not received. No related quality issues were identified during the investigation. There is no impact to product quality. No root cause or corrective/preventative actions were identified as the complaint was not confirmed. All release testing performed prior to the release of the reported batch was within specifications.  No follow-up attempts are needed. No further information is expected.